MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2019.07.035

Медицинская библиотека · Journal of the American College of Cardiology · 2019

Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.

Etminan Mahyar, Sodhi Mohit, Ganjizadeh-Zavareh Saeed, Carleton Bruce, Kezouh Abbas, Brophy James M

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Recent studies have linked fluoroquinolones (FQs) to cardiac adverse events, including aortic dissection and aneurysm. To date, whether FQs can increase the risk of aortic or mitral regurgitation has not been studied.

OBJECTIVES

This disproportionality analysis and case-control study examined whether FQs increase the risk of aortic and mitral regurgitation.

METHODS

Data from the U.S. Food and Drug Administration's adverse reporting system database was used to undertake a disproportionality analysis, and a random sample of 9,053,240 patients from the U.S. PharMetrics Plus database (IQVIA) was used for the matched nested case-control study. Current FQ exposure implied an active prescription at the index date or 30 days prior to the event date. Recent FQ exposure was defined as FQ use within days 31 to 60 and past within days 61 to 365 prior to the event date. Rate ratios (RRs) were compared to users of amoxicillin and azithromycin. Conditional logistic regression was used to compute RRs adjusting for confounders.

RESULTS

The reported odds ratio for the disproportionality analysis was 1.45 (95% confidence interval [CI]: 1.20 to 1.77). A total of 12,505 cases and 125,020 control subjects were identified in the case-control study. The adjusted RRs for current users of FQ compared with amoxicillin and azithromycin users were 2.40 (95% CI: 1.82 to 3.16) and 1.75 (95% CI: 1.34 to 2.29), respectively. The adjusted RRs for recent and past FQ users when compared with amoxicillin were 1.47 (95% CI: 1.03 to 2.09) and 1.06 (95% CI: 0.91 to 1.21), respectively.

CONCLUSIONS

These results show that the risk of aortic and mitral regurgitation is highest with current use followed by recent use. No risk was observed with past use of FQs. Future studies are necessary to confirm or refute these associations.

Для цитирования: Etminan Mahyar, Sodhi Mohit, Ganjizadeh-Zavareh Saeed, Carleton Bruce, Kezouh Abbas, Brophy James M. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.. Journal of the American College of Cardiology. 2019. DOI: 10.1016/j.jacc.2019.07.035.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.